Skip to main content

Upsher-Smith expands partnership with Appco

The collaboration is part of Upsher-Smith’s effort to grow its portfolio of products through strategic partnerships and product acquisitions.

Upsher-Smith has expanded its ongoing partnership with Appco with the addition of a near-term generic product opportunity to its portfolio.

The company said that the collaboration is part of Upsher-Smith’s company-wide effort to grow its portfolio of products through strategic partnerships and product acquisitions.

“This agreement further expands an already solid working relationship between Upsher-Smith and Appco. Appco has extensive skills and experience in the development of diverse dosage forms that span a wide range of therapeutic areas,” said Rich Fisher, president and COO of Upsher-Smith.

[Read more: Upsher-Smith intros three new dosage strengths for generic Absorica

“Our long-standing partnership has yielded a number of commercial-stage products. We are pleased to add their development strengths to our core competencies and expand Upsher-Smith’s product portfolio to accelerate growth in the United States,” he said.

“We are pleased to add one more product to our partnership with Upsher-Smith,” said Srini Paruchuri, chief operating officer at Appco. “Appco highly values Upsher-Smith’s strength in sales and marketing, which complements Appco’s development and manufacturing capabilities. We look forward to expanding and growing this partnership.’’

Upsher-Smith also said that it will open a manufacturing facility in Maple Grove, Minn., later this year. The new 270,000-sq.-ft. facility will have fully up-to-date serialization and packaging capabilities, as well as the capacity and capabilities that can support contract manufacturing for third parties.

Read more: Upsher-Smith, Emphascience ink deal for specialty branded generic product

This ad will auto-close in 10 seconds